ArticleFrontiers in medicine2025
Intelligent Alzheimer's diagnosis and disability assessment: robust medical imaging analysis using ensemble learning with ResNet-50 and EfficientNet-B3.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorder Alzheimer's disease (AD) has progressive characteristics and leads to severe cognitive impairment that reduces life quality. Disease management along with effective intervention depends on the detailed diagnosis conducted early. The proposed framework builds an ensemble system from ResNet-50 and EfficientNet-B3 to conduct automated AD diagnostics by processing high-resolution Magnetic Resonance Imaging (MRI) images. The proposed model uses ResNet-50 to extract features coupled with EfficientNet-B3 as its robust classifier which achieves high accuracy alongside generalization performance. A large, high-quality dataset comprising 33,984 MRI images was used, ensuring diverse representation of different disease stages: the study included participants with four dementia stages organized as Mild, Moderate, Non-demented, and Very Mild Demented. The research applied several comprehensive data preprocessing methods combining normalization steps with rescaling algorithms alongside noise elimination techniques to achieve enhanced performance. Performance tests on the model required examination of accuracy along with precision and recall metrics and F1-score and ROC curve area measurements. The ensemble model delivered remarkable overall accuracy reaching 99.32% while surpassing separate deep learning architectures. The confusion matrix evaluation results showed superb classification results for Mild and Moderate stages along with non-dementia cases while maintaining minimal Wrong choices in Very Mild Demented cases. Experimental findings demonstrate the strength of deep learning algorithms to detect AD disease stages accurately. The robust and accurate performance of the proposed model indicates it has potential for use in medical environments to support radiologists in their work of early-stage AD screening and treatment development. Additional research in diverse clinical environments will strive to optimize and validate the model so it can meet real-world diagnostic requirements for medical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.